Due to recent changes in the official account push mechanism, we welcome you to set Boom Health as a "starred" account on the homepage of the official account to get the latest trends and expert insights in the digital healthcare industry第一时间!
01 Global Digital Health Investment and Financing OverviewTumor Care Services Provider Employer Direct Healthcare Secures $92 Million in FinancingOn December 19, tumor care services provider Employer Direct Healthcare received a $92 million secondary investment from Insight Partners, bringing the company's valuation to $1 billion. Moving forward, EDH will continue to expand Cancer Care Direct, the industry's first end-to-end oncology solution, and establish several key partnerships with national healthcare programs, navigators, and other leading employer solutions in the field.Kimia Therapeutics, a platform for automated drug synthesis and screening, raises $55 million in Series A fundingOn December 19, Kimia Therapeutics, an automated drug synthesis and screening platform, secured $55 million in Series A funding, led by Column Group and Dimension. The funds will be used to expand the ATLAS platform and identify a broad range of therapeutic targets in oncology, immunology, and inflammation, while continuing collaboration with Carmot Therapeutics Inc. on key metabolic projects.AI Drug Discovery Company Deep Apple Therapeutics Completes $52 Million Series A FinancingOn December 18, AI drug discovery company Deep Apple Therapeutics completed a $52 million Series A financing round. Deep Apple generates simulated libraries through artificial intelligence (AI) to discover innovative small molecule therapies targeting high-value targets. Its discovery engine is applicable across a wide range of disease areas and is particularly well-suited for the accelerated discovery of full-length membrane proteins.Health Management Platform Twin Health Secures $50 Million in FinancingOn December 13, health management platform Twin Health secured $50 million in funding. This round was led by Temasek, with participation from existing investors ICONIQ Growth, Sofina, Peak XV, and Helena. The funds will be used to further expand its breakthrough technology and clinical service solutions for more members across the United States, as well as to broaden its pioneering Whole Body Digital Twin™ technology and services aimed at reversing chronic metabolic diseases.AI Drug Developer Unnatural Products Secures $32 Million in Series A FundingOn December 19, AI drug discovery company Unnatural Products secured $32 million in Series A funding. This round was led by Merck Global Health Innovation Fund and ARTIS Ventures. The proceeds will be used to advance UNP's innovative platform and expand its business scope beyond oncology to address a broader range of medical challenges.AI Tumor Drug R&D Platform Provider ImpriMed Secures $23 Million in Series A FundingOn December 19, AI-driven oncology drug discovery platform provider ImpriMed secured $23 million in Series A funding, led by SBVA. The company is committed to leveraging artificial intelligence to improve cancer treatment and plans to use the funds to expand its drug response prediction technology from veterinary to human oncology, increase headcount, and broaden business development and R&D pipelines.Metabolic Health and Primary Care Service Provider Knownwell Completes $20 Million Series A FinancingOn December 19, Knownwell, a provider of metabolic health and primary care services, completed a $20 million Series A financing round led by Andreessen Horowitz, with participation from existing investor Flare Capital Partners.Gene Sequencing Analysis Platform ME Instruments Completes Nearly 100 Million Yuan B++ Round FinancingRecently, ME Instruments, a gene sequencing and analysis platform, has completed a nearly RMB 100 million B++ round of financing, jointly invested by Lianyungang Talent Venture Capital Fund managed by Tianhui Capital and Jiangsu Jinqiao Private Equity Fund, among other institutions. The funds will be mainly used for the construction of a large-scale gene sequencing platform production base in Lianyungang, Jiangsu, promoting the mass production of sequencers and building a market promotion network, as well as accelerating the medical device registration application for the sequencers.Clinical Research CRO Service Provider Bonacia (Hefei) Pharmaceutical Technology Co., Ltd. Completes Nearly 100 Million Yuan B1 Round FinancingOn December 18, Bonacia (Hefei) Pharmaceutical Technology Co., Ltd., a clinical research CRO service provider, completed a nearly RMB 100 million Series B1 financing round. This round was led by Cornerstone Capital, with participation from Jinhe Capital, and Probe Capital served as the financial advisor. The proceeds from this financing will help the company vigorously promote its internationalization and digital intelligence business, further expanding into the North American and Southeast Asian markets.Personalized Veterinary Care Provider Dr. Treat Secures $10.5 Million in Seed FundingOn December 18, Dr. Treat, a provider of personalized veterinary care services, secured $10.5 million in seed funding. This round was led by Y Combinator, Liquid2, Epic Ventures, Quarry Ventures, Builders VC, Garuda Ventures, Scrum Ventures, UpHonest Capital, and Rebel Fund. The company is developing a new data platform to transform veterinary care.Beijing Xijian Technology Co., Ltd. Completes Tens of Millions of Yuan in Pre-A+ Round Financing for Human Soft Tissue Mechanics Imaging PlatformRecently, Beijing Xijian Technology Co., Ltd., a human soft tissue biomechanics imaging platform, has completed a Pre-A+ round of financing worth tens of millions of yuan, led by Yizhuang Capital. The funds from this round will be used for product development, team expansion, and market promotion. The company focuses on sports rehabilitation, skin aesthetics, and the diagnosis and treatment of major diseases, providing the industry with human soft tissue biomechanics imaging equipment and co-building an intervention ecosystem based on human biomechanics imaging.Personalized Nutrition Provider Season Health Secures $7 Million in FinancingOn December 18, personalized nutrition solution provider Season Health secured $7 million in funding from investors including Inception Health and Ziegler Link-age Fund. The company plans to use the funds to develop and promote its "Food as Medicine" programs, including initiatives targeting diabetes and high-risk pregnancies. Additionally, the company will expand its partnerships with suppliers and payers.AI Clinical Analysis Platform KAID Health Secures New FundingOn December 18, KAID Health, an artificial intelligence clinical analysis platform, secured new funding, the amount of which was undisclosed. Participants in this round of financing included Activate Venture Partners, Martinson Ventures, Boston Millennia Partners, Brandon Hull, and the KAID Health board of directors. The company plans to use the funds to strengthen its market share among healthcare providers and their payer partners, as well as to significantly expand its services.02 Digital Health Industry Dynamics
Harbour BioMed Licenses MSLN ADC to PfizerOn December 15, Harbour BioMed reached a licensing agreement with Pfizer. Harbour BioMed's subsidiary, Harbour BioMed (Suzhou) Co., Ltd, licensed the global rights of the MSLN ADC new drug HBM9033 to Seagen, a subsidiary of Pfizer. The latter paid $53 million as an upfront and near-term payment, up to $1.05 billion in milestone payments, and tiered royalties ranging from high single-digit to high teens percentages.Nona Biosciences Announces Exclusive License Agreement with PfizerOn December 15, Nona Biosciences announced an exclusive licensing agreement with Pfizer for the global clinical development and commercialization of its MSLN-targeted antibody-drug conjugate (ADC) HBM9033, with a total transaction value of up to approximately $1.1 billion. HBM9033 is a potential best-in-class ADC drug co-developed by Nona Biosciences and MediLink Therapeutics, which specifically targets the human MSLN protein.Fosun Pharma Partners with Insightec to Establish Joint Venture in ChinaOn December 13, Fosun Pharma announced the official signing of a cooperation agreement with Insightec. The two parties will jointly establish Fosun Medison Medical Technology Co., Ltd. in China. Fosun Medison will focus on the commercial expansion, clinical application, and research of the MRI-guided focused ultrasound brain treatment system in the Chinese market, helping Parkinson's disease patients and essential tremor patients regain a high-quality life.SystImmune and Bristol-Myers Squibb Reach Exclusive Licensing and Cooperation AgreementOn December 12, SystImmune, a subsidiary of Biokin, and Bristol-Myers Squibb announced an exclusive licensing and collaboration agreement for BL-B01D1, developed by SystImmune, for the treatment of lung cancer, breast cancer, and potentially other types of cancer. Bristol-Myers Squibb will pay SystImmune an upfront payment of $800 million and potential near-term payments of up to $500 million, with the total potential transaction value reaching up to $8.4 billion.03 Global Digital Health M&A OverviewCarl Zeiss Acquires Dutch Ophthalmology Research CenterOn December 15, Carl Zeiss Meditec announced that it would acquire 100% of the equity of the Dutch Ophthalmic Research Center (DORC) from the French investment company Eurazeo for a total price of 985 million euros (approximately 7.6 billion RMB). DORC focuses on the research, development, and provision of highly innovative ophthalmic products and solutions. Its product line covers ophthalmic surgical equipment, disposable supplies, and liquid products, which are widely used in the treatment of various ophthalmic diseases, including retinal diseases, cataracts, glaucoma, and refractive errors.AstraZeneca Acquires Vaccine Developer Icosavax for $1.1 BillionOn December 13, AstraZeneca announced that it had reached a definitive agreement to acquire Icosavax. The key asset of this acquisition is the candidate drug IVX-A12, which is in the late-stage development pipeline and represents the most advanced vaccine in development targeting RSV and hMPV. The upfront and maximum potential value of the deal totals approximately $1.1 billion. Icosavax focuses on developing differentiated, high-potential vaccines using an innovative virus-like particle (VLP) platform. IVX-A12 is a potentially "first-in-class" VLP combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).ArteryNet/Arterial Orange Industry Think Tank/China Renaissance/CGP/Rock Health/Mobile Health News/FierceHealth, etc.
Compiled by: Zhang Qiankun
